The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis. [electronic resource]
Producer: 20190102Description: 323-331 p. digitalISSN:- 1476-5551
- Adaptor Proteins, Signal Transducing -- genetics
- Animals
- Cell Death -- drug effects
- Epigenesis, Genetic -- drug effects
- Gene Rearrangement -- drug effects
- Heterografts -- drug effects
- Histone Deacetylase Inhibitors -- pharmacology
- Histone Deacetylases -- metabolism
- Histone-Lysine N-Methyltransferase -- genetics
- Histones -- genetics
- Humans
- Mice
- Myeloid-Lymphoid Leukemia Protein -- genetics
- Panobinostat -- pharmacology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Ubiquitin-Protein Ligases -- genetics
- Ubiquitination -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.